LPCN
Price:
$6.09
Market Cap:
$32.57M
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1144, an oral prodrug of bioidentical testosterone that has completed Phase II clinical trial for the treatment of non-cirrhotic non-alcoholic steatohepatitis; LPCN 1111, an oral prodrug of testosterone tridecanoate for once daily dosing, which has completed Phase II clinical trial ...[Read more]
Industry
Biotechnology
IPO Date
2013-10-22
Stock Exchange
NASDAQ
Ticker
LPCN
According to Lipocine Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 27.02M. This represents a change of 31.28% compared to the average of 20.58M of the last 4 quarters.
The mean historical Enterprise Value of Lipocine Inc. over the last ten years is 55.25M. The current 27.02M Enterprise Value has changed 4.79% with respect to the historical average. Over the past ten years (40 quarters), LPCN's Enterprise Value was at its highest in in the December 2015 quarter at 216.22M. The Enterprise Value was at its lowest in in the December 2019 quarter at 9.22M.
Average
55.25M
Median
47.15M
Minimum
7.39M
Maximum
192.10M
Discovering the peaks and valleys of Lipocine Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 730.75%
Maximum Annual Enterprise Value = 192.10M
Minimum Annual Increase = -75.15%
Minimum Annual Enterprise Value = 7.39M
Year | Enterprise Value | Change |
---|---|---|
2023 | 9.76M | -68.17% |
2022 | 30.66M | -44.26% |
2021 | 55.00M | -10.43% |
2020 | 61.41M | 730.75% |
2019 | 7.39M | -75.15% |
2018 | 29.74M | -54.61% |
2017 | 65.53M | 6.44% |
2016 | 61.57M | -67.95% |
2015 | 192.10M | 388.68% |
2014 | 39.31M | 155.11% |
The current Enterprise Value of Lipocine Inc. (LPCN) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
31.80M
5-year avg
32.84M
10-year avg
55.25M
Lipocine Inc.’s Enterprise Value is less than Sigilon Therapeutics, Inc. (43.98M), less than Reviva Pharmaceuticals Holdings, Inc. (28.64M), greater than ZyVersa Therapeutics, Inc. (1.84M), greater than Kiromic BioPharma, Inc. (10.92M), less than Unicycive Therapeutics, Inc. (50.32M), less than Checkpoint Therapeutics, Inc. (149.72M), greater than Mustang Bio, Inc. (6.13M), less than Fortress Biotech, Inc. (59.91M), less than Kodiak Sciences Inc. (161.73M), less than Ardelyx, Inc. (1.45B), less than Zura Bio Limited (90.25M), greater than Hepion Pharmaceuticals, Inc. (1.72M), greater than AVROBIO, Inc. (-85302404.00), less than Verastem, Inc. (115.44M), less than Reviva Pharmaceuticals Holdings, Inc. (0), less than Eyenovia, Inc. (28.64M), less than Cognition Therapeutics, Inc. (57.71M), greater than TransCode Therapeutics, Inc. (-8869924.00), greater than null (5.76M),
Company | Enterprise Value | Market cap |
---|---|---|
43.98M | $56.22M | |
28.64M | $33.39M | |
1.84M | $1.96M | |
10.92M | $1.73M | |
50.32M | $45.28M | |
149.72M | $154.67M | |
6.13M | $9.32M | |
59.91M | $49.59M | |
161.73M | $205.20M | |
1.45B | $1.40B | |
90.25M | $278.69M | |
1.72M | $3.68M | |
-85302404.00 | $5.24M | |
115.44M | $156.95M | |
0 | $36.43M | |
28.64M | $44.32M | |
57.71M | $19.04M | |
-8869924.00 | $8.89M | |
5.76M | $0 |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Lipocine Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Lipocine Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Lipocine Inc.'s Enterprise Value?
What is the highest Enterprise Value for Lipocine Inc. (LPCN)?
What is the 3-year average Enterprise Value for Lipocine Inc. (LPCN)?
What is the 5-year average Enterprise Value for Lipocine Inc. (LPCN)?
How does the current Enterprise Value for Lipocine Inc. (LPCN) compare to its historical average?